Cure of a patient with profoundly chemotherapy-refractory primary mediastinal large B-cell lymphoma: Role of rituximab, high-dose therapy, and allogeneic stem cell transplantation

References

• Harris NL, Jaffe ES, Diebold J et al. The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Ann Oncol 1999;1O:1419— 1432.
   Google Scholar
• Harris NL, Jaffe ES, Stein H et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994;84:1361–1392.
   PubMed Web of Science ®Google Scholar
• Rosenwald A, Wright G, Leroy K et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favourable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med 2003;198:851–862.
   PubMed Web of Science ®Google Scholar
• Savage KJ, Monti S, Kutok JL et al. The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. Blood 2003;102:3871–3879.
   PubMed Web of Science ®Google Scholar
• van Besien K, Kelta M, Bahaguna P. Primary mediastinal B-cell lymphoma: a review of pathology and management. J Chin Oncol 2001;19:1855–1864.
   Google Scholar
• Philip T, Armitage JO, Spitzer G et al. High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. N Engl J Med 1987;316:1493–1498.
   PubMed Web of Science ®Google Scholar
• Popat U, Przepiork D, Champlin R et al. High-dose chemotherapy for relapsed and refractory diffuse large B-cell lymphoma: mediastinal localization predicts for a favourable outcome. J Chin Oncol 1998;16:63–69.
   PubMed Web of Science ®Google Scholar
• Sehn LH, Antin JH, Shulman LN et al. Primary diffuse large B-cell lymphoma of the mediastinum: outcome following high-dose chemotherapy and autologous hematopoietic cell transplantation. Blood 1998;91:717–723.
   PubMed Web of Science ®Google Scholar
• Freytes CO, Loberiza FR, Rizzo JD et al. Myeloablative allogeneic hematopoietic stem cell transplantation in patients who experience relapse after autologous stem cell transplanta-tion for lymphoma: a report of the International Bone Marrow Transplant Registry. Blood 2004;104:3797–3803.
   PubMed Web of Science ®Google Scholar
• Peggs KS, MacKinnon S, Linch DC. The role of allogeneic transplantation in non-Hodgkin's lymphoma. Br J Haematol 2005;128:153–168.
   PubMed Web of Science ®Google Scholar
• Escalon MP, Champlin RE, Saliba RM et al. Nonmyeloa-blative allogeneic hematopoietic transplantation: a promising salvage therapy for patients with non-Hodgkin's lymphoma whose disease has failed a prior autologous transplantation. J Chin Oncol 2004;22:2419–2423.
   PubMed Web of Science ®Google Scholar
• Ratei R, Matylis A, Krahl D et al. Salvage therapy for relapsed mediastinal B-cell lymphoma with allogeneic HLA identical related donor bone marrow transplantation, donor lympho-cyte infusion and IDEC-C2B8. Leuk Lymph 2000;40:133–140.
   PubMed Web of Science ®Google Scholar
• Bierman PJ. Allogeneic bone marrow transplantation for lymphoma. Blood Rev 2000;14:1–13.
   PubMed Web of Science ®Google Scholar
• Kewalramani T, Zelenetz AD, Nimer SD et al. Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. Blood 2004;103:3684–3688.
   PubMed Web of Science ®Google Scholar
• Khouri IF, Romaguera J, Kantarjian H et al. Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma. J Chin Oncol 1998;12:3803–3809.
   Google Scholar
• Seymour JF, Grigg AP, Szer J, Fox RM. Fludarabine and mitoxantrone: effective and well-tolerated salvage therapy in relapsed indolent lymphoproliferative disorders. Ann Oncol 2001;12:1455–1460.
   PubMed Web of Science ®Google Scholar
• Seymour JF, Grigg AP, Szer J, Fox RM. Cisplatin, fludar-abine, and cytarabine: a novel, pharmacologically designed salvage therapy for patients with refractory, histologically aggressive or mantle cell non-Hodgkin's lymphoma. Cancer 2002;94:585–593.
   PubMed Web of Science ®Google Scholar
• Hamlin PA, Zelenetz AD, Kewalramani T et al. Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma. Blood 2003;102:1989–1996.
   PubMed Web of Science ®Google Scholar
• Patti C, Majolino I, Scime R et al. High-dose cyclopho-sphamide, etoposide and BCNU (CVB) with autologous stem cell rescue in malignant lymphomas. Eur J Haematol 1993;51:18–24.
   PubMed Web of Science ®Google Scholar
• Khouri IF, Saliba RM, Giralt SA et al. Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality. Blood 2001;98:3595–3599.
   PubMed Web of Science ®Google Scholar
• T azzarino M, Orlandi E, Paulli M et al. Primary mediastinal B-cell lymphoma with sclerosis: an aggressive tumor with distinctive clinical and pathologic features. J Chin Oncol 1993;11:2306–2313.
   PubMed Web of Science ®Google Scholar
• Hoerr AL, Gao F, Hidalgo J et al. Effects of pretransplantation treatment with rituximab on outcomes of autologous stem-cell transplantation for non-Hodgkin's lymphoma. J Chin Oncol 2004;22:4561–4566.
   PubMed Web of Science ®Google Scholar
• Culic S, Culic V, Armanda V, Kuljis D, Pesutic-Pisac V, Jankovic S. Anti-CD20 monoclonal antibody (Rituximab) for therapy of mediastinal CD20-positive large B-cell non-Hodgkin lymphoma with a local tumor extension into the lung of a 10-year-old girl. Pediatr Hematol Oncol 2003;20: 339–344.
   Google Scholar
• Voudouris D, Sanmugarajah J, Podrumar A, Gruenstein S, Levine RL. Primary mediastinal B cell lymphoma (PMBL) in two sisters. 38th ASCO Annual Meeting; 2002 May 18–21; Orlando. Proc Am Soc Chin Oncol 2002;21:207b (abstract 2646).
   Google Scholar
• Vose JM, Anderson JR, Kessinger A et al. High-dose chemotherapy and autologous hematopoietic stem-cell trans-plantation for aggressive non-Hodgkin's lymphoma. J Chin Oncol 1993;11:1846–1851.
   PubMed Web of Science ®Google Scholar
• Bishop MR. The graft-versus-lymphoma effect: fact, fiction, or opportunity? J Chin Oncol 2003;21:3713–3715.
   PubMed Web of Science ®Google Scholar
• Mollee P, Lazarus HM, Lipton J. Why aren't we performing more allografts for aggressive non-Hodgkin's lymphoma? Bone Marrow Transplant 2003;11:953–960.
   Google Scholar
• Robinson SP, Goldstone AH, Mackinnon S et al. Chemore-sistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell trans-plantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplan-tation. Blood 2002;100:4310–4316.
   PubMed Web of Science ®Google Scholar